Coherus BioSciences, Inc. (CHRS)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CHRS Insider Trading Activity
CHRS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Insider Activity of Coherus BioSciences, Inc.
Over the last 12 months, insiders at Coherus BioSciences, Inc. have bought $0 and sold $0 worth of Coherus BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Coherus BioSciences, Inc. have bought $49,668 and sold $6.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,700 shares for transaction amount of $49,668 was made by Stilwell McDavid (Chief Financial Officer) on 2021‑06‑09.
List of Insider Buy and Sell Transactions, Coherus BioSciences, Inc.
| 2023-11-22 | Sale | Lanfear Dennis M | President & CEO | 223,100 0.2098% | $2.02 | $449,770 | -6.44% | |
| 2021-10-15 | Sale | Stilwell McDavid | Chief Financial Officer | 3,507 0.0045% | $16.80 | $58,919 | -30.65% | |
| 2021-09-29 | Sale | HEALY JAMES | director | 286,076 0.3546% | $16.12 | $4.61M | -26.09% | |
| 2021-09-28 | Sale | HEALY JAMES | director | 48,329 0.0622% | $17.17 | $829,809 | -27.59% | |
| 2021-09-27 | Sale | HEALY JAMES | director | 100,150 0.1287% | $18.06 | $1.81M | -30.86% | |
| 2021-06-09 | Stilwell McDavid | Chief Financial Officer | 3,700 0.0049% | $13.42 | $49,668 | +0.96% | ||
| 2021-06-08 | Sale | Lanfear Dennis M | President & CEO | 31,054 0.0411% | $13.56 | $421,229 | +0.59% | |
| 2021-03-09 | Sale | Vexler Vladimir | Chief Scientific Officer | 114,240 0.1583% | $16.25 | $1.86M | -9.44% | |
| 2021-03-05 | Sale | Anicetti Vincent R | Chief Operating Officer | 26,649 0.0357% | $15.46 | $412,065 | -7.55% | |
| 2021-02-17 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,488 0.0034% | $17.45 | $43,418 | -13.71% | |
| 2021-02-01 | Sale | Viret Jean-Frederic | Chief Financial Officer | 7,402 0.0124% | $21.55 | $159,513 | -13.35% | |
| 2021-01-25 | Sale | Viret Jean-Frederic | Chief Financial Officer | 46,144 0.0647% | $19.95 | $920,736 | -21.18% | |
| 2021-01-19 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,500 0.0034% | $17.94 | $44,852 | -13.26% | |
| 2020-12-17 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,500 0.0034% | $17.51 | $43,780 | -10.94% | |
| 2020-12-10 | Sale | Vexler Vladimir | Chief Scientific Officer | 17,626 0.0246% | $18.05 | $318,066 | -11.68% | |
| 2020-12-09 | Sale | Vexler Vladimir | Chief Scientific Officer | 49,512 0.0685% | $18.24 | $903,084 | -13.28% | |
| 2020-12-07 | Sale | Anicetti Vincent R | Chief Operating Officer | 8,791 0.0122% | $18.42 | $161,896 | -13.80% | |
| 2020-12-04 | Sale | Anicetti Vincent R | Chief Operating Officer | 49,000 0.0675% | $18.85 | $923,694 | -16.42% | |
| 2020-12-03 | Sale | Anicetti Vincent R | Chief Operating Officer | 49,756 0.0692% | $18.67 | $929,079 | -14.87% | |
| 2020-11-18 | Sale | Anicetti Vincent R | Chief Operating Officer | 4,283 0.006% | $18.00 | $77,094 | -11.09% |
Insider Historical Profitability
| LILLY ELI & CO | 3042019 2.6249% | $2.8M | 1 | 0 | +82.59% | |
| Lanfear Dennis M | President & CEO | 731693 0.6314% | $673,230.73 | 0 | 10 | |
| FMR LLC | 361594 0.312% | $332,702.64 | 0 | 3 | ||
| Troendle August J. | director | 268428 0.2316% | $246,980.60 | 0 | 3 | |
| Richards Christos | director | 63836 0.0551% | $58,735.50 | 0 | 2 | |
| Viret Jean-Frederic | Chief Financial Officer | 61295 0.0529% | $56,397.53 | 0 | 24 | |
| Anicetti Vincent R | Chief Operating Officer | 53402 0.0461% | $49,135.18 | 0 | 25 | |
| Vexler Vladimir | Chief Scientific Officer | 53386 0.0461% | $49,120.46 | 0 | 3 | |
| Herman Alan C. | Chief Scientific Officer | 49651 0.0428% | $45,683.89 | 0 | 26 | |
| FINCK BARBARA K | Chief Medical Officer | 37043 0.032% | $34,083.26 | 0 | 5 | |
| Stilwell McDavid | Chief Financial Officer | 31611 0.0273% | $29,085.28 | 1 | 1 | +0.96% |
| HEALY JAMES | director | 0 0% | $0 | 1 | 8 | +82.59% |
| Szela Mary T | director | 0 0% | $0 | 0 | 1 | |
| Wahlstrom Mats | director | 0 0% | $0 | 0 | 7 | |
| Watler Peter K. | Chief Technical Officer | 0 0% | $0 | 0 | 7 |
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $111.89M | |
$22,597,521 | 91 | 4.59% | $104.68M | |
$47,282,828 | 47 | -17.38% | $96.94M | |
$36,079,815 | 31 | 43.23% | $103.59M | |
$26,678,853 | 21 | -5.95% | $98.47M | |
$294,424,120 | 20 | 1.33% | $107.89M | |
$111,692,551 | 18 | 13.51% | $107.79M | |
$178,593,887 | 15 | -14.86% | $97.46M | |
$398,999,793 | 13 | -14.11% | $117.14M | |
$13,919,584 | 9 | -30.43% | $115.72M | |
$68,692,148 | 6 | -39.10% | $116.57M | |
$401,951 | 4 | 57.41% | $100.9M | |
$58,352 | 4 | -43.78% | $99.92M | |
$40,000,000 | 3 | -16.24% | $100.29M | |
Coherus BioSciences, Inc. (CHRS) | $16,003,671 | 3 | 55.38% | $106.63M |
$73,632,168 | 3 | -63.24% | $111.74M | |
$9,999,990 | 2 | 25.53% | $101.51M | |
$20,020,000 | 1 | -75.24% | $107.93M | |
$3,620 | 1 | 94.16% | $108.43M |
CHRS Institutional Investors: Active Positions
| Increased Positions | 58 | +33.14% | 11M | +13.67% |
| Decreased Positions | 73 | -41.71% | 23M | -29.19% |
| New Positions | 27 | New | 6M | New |
| Sold Out Positions | 40 | Sold Out | 9M | Sold Out |
| Total Postitions | 160 | -8.57% | 66M | -15.53% |
CHRS Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $12,381.00 | 9.62% | 11.15M | -156,306 | -1.38% | 2024-12-31 |
| Blackrock, Inc. | $12,294.00 | 9.55% | 11.08M | -876,038 | -7.33% | 2024-12-31 |
| Point72 Asset Management, L.P. | $5,864.00 | 4.56% | 5.28M | +5M | New | 2024-12-31 |
| Rubric Capital Management Lp | $5,837.00 | 4.53% | 5.26M | -5M | -49.44% | 2024-12-31 |
| Tang Capital Management Llc | $4,052.00 | 3.15% | 3.65M | +1M | +55.32% | 2024-12-31 |
| Kohlberg Kravis Roberts & Co. L.P. | $3,370.00 | 2.62% | 3.04M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $2,886.00 | 2.24% | 2.6M | +34,494 | +1.34% | 2024-12-31 |
| State Street Corp | $2,417.00 | 1.88% | 2.18M | +150,699 | +7.44% | 2024-12-31 |
| Morgan Stanley | $2,344.00 | 1.82% | 2.11M | +1M | +155.3% | 2024-12-31 |
| Cm Management, Llc | $2,276.00 | 1.77% | 2.05M | +50,000 | +2.5% | 2024-12-31 |